MD Anderson and Virogin Biotech collaborate to advance the development of investigational oncolytic viruses, treatments

The University of Texas MD Anderson Cancer Center and Virogin Biotech today announced a strategic collaboration to accelerate the development of investigational treatments, including oncolytic viruses and immunotherapies, for patients with advanced cancers.

The agreement brings together MD Anderson's clinical trials expertise and infrastructure with Virogin's innovative pipeline of investigational oncolytic viruses. The five-year collaboration will support the clinical development of Virogin's therapies with multiple clinical trials in various cancer types to evaluate the safety and clinical benefit of these therapies and to identify prognostic biomarkers of response.

Our collaboration with MD Anderson to advance the clinical development of our products is an important step toward our goal of providing new treatment options for patients with high unmet medical needs worldwide."

Ronghua Zhao, M.D., chief medical officer of Virogin Biotech

Virogin's viral therapies are engineered to directly eliminate tumor cells and to stimulate both innate and adaptive anti-tumor immune responses. The initial clinical study will evaluate Virogin's VG201 in advanced tumors. VG201 is a first-in-class oncolytic HSV-1 virus that has enhanced oncolytic activity specifically for tumors expressing carcinoembryonic antigen (CEA) and is designed to produce immune-stimulating cytokines IL-12 and IL-15/IL15Rα.

Together with the clinical trials, the collaboration also will support translational research at MD Anderson to uncover valuable insights into the anti-tumor activity of virotherapies and the role of various payloads in changing the tumor-microenvironment.

"Oncolytic viruses hold the potential to be highly specific therapies that boost anti-tumor immune responses, offering opportunities for synergistic combinations with immune checkpoint blockade and other immunotherapies," said Siqing Fu, M.D., Ph.D., professor of Investigational Cancer Therapeutics at MD Anderson. "We are pleased to collaborate with Virogin in this effort to accelerate the development of these novel cancer therapies."